270 related articles for article (PubMed ID: 27090640)
1. Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Cristóbal I; Rojo F; Madoz-Gúrpide J; García-Foncillas J
Mol Cell Biol; 2016 Jun; 36(12):1734-9. PubMed ID: 27090640
[TBL] [Abstract][Full Text] [Related]
2. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
[TBL] [Abstract][Full Text] [Related]
3. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1.
Kim JS; Kim EJ; Oh JS; Park IC; Hwang SG
Cancer Res; 2013 Nov; 73(22):6667-78. PubMed ID: 23983103
[TBL] [Abstract][Full Text] [Related]
4. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
Hou X; Li Z; Huang W; Li J; Staiger C; Kuang S; Ratliff T; Liu X
Prostate; 2013 Sep; 73(12):1352-63. PubMed ID: 23661607
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic relevance of the protein phosphatase 2A in cancer.
Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
[TBL] [Abstract][Full Text] [Related]
7. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis.
Deeraksa A; Pan J; Sha Y; Liu XD; Eissa NT; Lin SH; Yu-Lee LY
Oncogene; 2013 Jun; 32(24):2973-83. PubMed ID: 22890325
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
Zhang Z; Chen L; Wang H; Ahmad N; Liu X
Cell Cycle; 2015; 14(13):2142-8. PubMed ID: 25927139
[TBL] [Abstract][Full Text] [Related]
9. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
[TBL] [Abstract][Full Text] [Related]
10. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Insights into the Selective Dual BET and PLK1 Inhibitory Activity of a Novel Benzamide Compound in Castration-Resistant Prostrate Cancer.
Akawa OB; Subair TI; Omolabi KF; Okunlola FO; Soliman MES
Chem Biodivers; 2021 Dec; 18(12):e2100519. PubMed ID: 34729902
[TBL] [Abstract][Full Text] [Related]
12. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
13. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.
Yu Z; Deng P; Chen Y; Liu S; Chen J; Yang Z; Chen J; Fan X; Wang P; Cai Z; Wang Y; Hu P; Lin D; Xiao R; Zou Y; Huang Y; Yu Q; Lan P; Tan J; Wu X
Adv Sci (Weinh); 2021 Dec; 8(23):e2100759. PubMed ID: 34881526
[TBL] [Abstract][Full Text] [Related]
15. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
16. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
18. Anti-mitotic therapies in cancer.
Tischer J; Gergely F
J Cell Biol; 2019 Jan; 218(1):10-11. PubMed ID: 30545842
[TBL] [Abstract][Full Text] [Related]
19. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase (Plk) 1 as a target for prostate cancer management.
Reagan-Shaw S; Ahmad N
IUBMB Life; 2005 Oct; 57(10):677-82. PubMed ID: 16223707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
